Royal London Asset Management Ltd. Purchases 409 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Royal London Asset Management Ltd. raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 0.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 44,084 shares of the biopharmaceutical company's stock after acquiring an additional 409 shares during the period. Royal London Asset Management Ltd.'s holdings in Regeneron Pharmaceuticals were worth $31,402,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the stock. State Street Corp boosted its stake in Regeneron Pharmaceuticals by 1.3% in the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company's stock worth $5,153,603,000 after purchasing an additional 61,277 shares in the last quarter. Amundi increased its stake in shares of Regeneron Pharmaceuticals by 45.8% in the 4th quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company's stock valued at $1,138,074,000 after buying an additional 487,489 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Regeneron Pharmaceuticals by 3.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 695,799 shares of the biopharmaceutical company's stock valued at $495,639,000 after buying an additional 22,538 shares during the period. Sumitomo Mitsui Trust Group Inc. raised its position in shares of Regeneron Pharmaceuticals by 0.4% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 302,616 shares of the biopharmaceutical company's stock worth $215,562,000 after acquiring an additional 1,108 shares during the last quarter. Finally, Candriam S.C.A. lifted its stake in shares of Regeneron Pharmaceuticals by 3.6% during the fourth quarter. Candriam S.C.A. now owns 261,498 shares of the biopharmaceutical company's stock valued at $186,273,000 after acquiring an additional 8,973 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Remove Ads

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Canaccord Genuity Group downgraded shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, December 17th. Sanford C. Bernstein cut their price target on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating on the stock in a research note on Tuesday, January 7th. Canaccord Genuity Group began coverage on Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They set a "hold" rating and a $165.00 target price for the company. Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, February 5th. Finally, Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and upped their price target for the company from $762.00 to $834.00 in a report on Wednesday, February 5th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $973.13.

Regeneron Pharmaceuticals Trading Down 4.1 %

NASDAQ REGN traded down $26.86 on Tuesday, hitting $634.14. The company's stock had a trading volume of 852,346 shares, compared to its average volume of 635,607. The company's 50-day moving average is $688.31 and its 200 day moving average is $809.71. The firm has a market cap of $69.33 billion, a PE ratio of 16.57, a PEG ratio of 2.34 and a beta of 0.27. Regeneron Pharmaceuticals, Inc. has a 1-year low of $642.00 and a 1-year high of $1,211.20. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating the consensus estimate of $11.21 by $0.86. The business had revenue of $3.79 billion for the quarter, compared to analysts' expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm's revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the business posted $11.86 earnings per share. As a group, analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were paid a $0.88 dividend. The ex-dividend date was Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.56%. Regeneron Pharmaceuticals's dividend payout ratio is currently 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.